The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
- 1 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 41 (9), 1246-1254
- https://doi.org/10.1038/s41401-020-0367-9
Abstract
Mitophagy is a degradative pathway that mediates the degradation of the entire mitochondria, and defects in this process are implicated in many diseases including cancer. In mammals, mitophagy is mediated by BNIP3L (also known as NIX) that is a dual regulator of mitochondrial turnover and programmed cell death pathways. Acute myeloid leukemia (AML) cells with deficiency of BNIP3L are more sensitive to mitochondria-targeting drugs. But small molecular inhibitors for BNIP3L are currently not available. Some immunomodulatory drugs (IMiDs) have been proved by FDA for hematologic malignancies, however, the underlining molecular mechanisms are still elusive, which hindered the applications of BNIP3L inhibition for AML treatment. In this study we carried out MS-based quantitative proteomics analysis to identify the potential neosubstrates of a novel thalidomide derivative CC-885 in A549 cells. In total, we quantified 5029 proteins with 36 downregulated in CRBN+/+ cell after CC-885 administration. Bioinformatic analysis showed that macromitophagy pathway was enriched in the negative pathway after CC-885 treatment. We further found that CC-885 caused both dose- and time-dependent degradation of BNIP3L in CRBN+/+, but not CRBN-/- cell. Thus, our data uncover a novel role of CC-885 in the regulation of mitophagy by targeting BNIP3L for CRL4CRBN E3 ligase-dependent ubiquitination and degradation, suggesting that CC-885 could be used as a selective BNIP3L degradator for the further investigation. Furthermore, we demonstrated that CC-885 could enhance AML cell sensitivity to the mitochondria-targeting drug rotenone, suggesting that combining CC-885 and mitochondria-targeting drugs may be a therapeutic strategy for AML patients.This publication has 30 references indexed in Scilit:
- Knockdown of BNIP3L or SQSTM1 alters cellular response to mitochondria target drugsAutophagy, 2019
- Evolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic ProcessPhysiological Reviews, 2019
- A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced MalignanciesClinical Cancer Research, 2019
- BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabineHaematologica, 2016
- BNIP3- and BNIP3L-Mediated Mitophagy Promotes the Generation of Natural Killer Cell MemoryImmunity, 2015
- Bnip3 as a Dual Regulator of Mitochondrial Turnover and Cell Death in the MyocardiumPediatric Cardiology, 2011
- Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathyProceedings of the National Academy of Sciences of the United States of America, 2010
- NIX is required for programmed mitochondrial clearance during reticulocyte maturationProceedings of the National Academy of Sciences of the United States of America, 2007
- Unrestrained erythroblast development in Nix −/− mice reveals a mechanism for apoptotic modulation of erythropoiesisProceedings of the National Academy of Sciences of the United States of America, 2007
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999